Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery of potent therapeutic agents. These modalities offer new opportunities in oncology and beyond but present complex challenges in design, conjugation, and optimization.

In this white paper, we examine the structural principles and technical hurdles that influence the success of antibody-targeted drugs and discuss strategies to mitigate risk and accelerate their development.